KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Leases (2020 - 2025)

Aquestive Therapeutics (AQST) has 6 years of Current Leases data on record, last reported at $631000.0 in Q4 2025.

  • For Q4 2025, Current Leases rose 23.73% year-over-year to $631000.0; the TTM value through Dec 2025 reached $631000.0, up 23.73%, while the annual FY2025 figure was $631000.0, 23.73% up from the prior year.
  • Current Leases reached $631000.0 in Q4 2025 per AQST's latest filing, up from $601000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $926000.0 in Q1 2022 and bottomed at $255000.0 in Q4 2022.
  • Average Current Leases over 5 years is $597200.0, with a median of $555000.0 recorded in 2025.
  • Peak YoY movement for Current Leases: crashed 71.64% in 2022, then surged 52.94% in 2023.
  • A 5-year view of Current Leases shows it stood at $899000.0 in 2021, then plummeted by 71.64% to $255000.0 in 2022, then skyrocketed by 52.94% to $390000.0 in 2023, then skyrocketed by 30.77% to $510000.0 in 2024, then increased by 23.73% to $631000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $631000.0 in Q4 2025, $601000.0 in Q3 2025, and $570000.0 in Q2 2025.